Menu
Clinical studies for CNS drugs have a much lower success rate for FDA approval than non-CNS drugs (6.2% vs 13.3%). Patient recruitment can also be challenging and costly. For Alzheimer’s drug studies, the screen failure rate in at-risk populations is typically 70-75%. ViewMind technology can help you speed up your screening, reduce its costs, ensure cohorts are cognitively matched, and measure the impact of new drugs.
ViewMind can reduce screen failure rates by more than 50% with a non-invasive, 15-minute pre-screening for better cohort harmonization and stratification that will boost the statistical significance of the results.
ViewMind can give you access to critical, frequently updated, individualized data to complement pathological biomarker results, so that you can achieve better patient outcomes.
“ViewMind’s technology applies to a range of neurocognitive conditions, an exceptional and unique value proposition. ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.
The company’s offering spans the diagnostic continuum, from early stage to disease progression, monitoring, response, and treatment.”
Assess brain health by cognitive domain as a non-invasive, scalable and accurate pre-screening.
Identify patients for treatment and frequently measure treatment progress throughout your clinical trial with an affordable solution.
Improve patient cohort harmonization, stratification and the statistical significance of clinical studies.
Measure the impact of a drug or a digital therapeutic on different cognitive domains of clinical trial participants.
ViewMind works for participants independent of age, educational levels, and cultural background.
Now you can facilitate inclusive studies that address diverse communities and healthcare disparities.
Measure individual patient response to treatment and monitor progress in short time intervals.
Usa a scalable, non-invasive test combined with precision cognition measurement.
Detect early subclinical disease and progression with much of the value of a PET, CSF and MRI but non-invasive and affordable.
Brain Health for Life
Easy to perform. Non-invasive.
Precision Neurology.
